University of Rochester Medical Center Wilmot Cancer Center

Strong Memorial Hospital

Rochester, NY
Website
(888) 850-0650Refer Patient

Accepting patients

STOMP

Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
Learn more
  • CELMoD
  • SINE
  • Phase 1/2

Accepting patients

MonumenTAL-1

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 2

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 3

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Randomization
  • Phase 3

Not yet accepting

QXL138AM

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Learn more
  • CD138
  • Phase 1
4 hidden based on your filters. Show All